Aspen Aerogels Inc

ASPN remains in a Stage 4 decline with a clear sequence of lower highs and lower lows, reinforced by downward-sloping EMAs and resistance at the 50 and 200 SMAs. Medium-term bias stays bearish, and short-term execution reads as neutral with price oscillating around flat/declining EMAs below major moving averages. We defer bearish execution, looking to trim into rallies toward the 9/21 EMA and the SMA 50/200 resistance zones.

• ↑Q2 revenue $49.8M (+32% QoQ)
• ↑Q3 guidance $65–80M signals 30–60% sequential growth
• ↓$5.3M incident costs from East Providence plant downtime